Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Henaro Sabino

Pediatric Cardiology Rome, GA Medical Doctor

NPI 1194763789 CMS profile 368892

504 Redmond Rd Nw, Rome, GA 30165

Open in the dashboard

General payments

$2,592

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Henaro Sabino of Rome, GA is reported in the CMS Open Payments database as having received $2,592 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Pediatric Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2024 General $862 25
2023 General $589 32
2022 General $306 16
2021 General $321 16
2020 General $307 20
2019 General $194 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Henaro Sabino
  • Pediatric Cardiology median
  • Middle half of Pediatric Cardiology
  • National median

In program year 2025, general payments to Henaro Sabino were reported at $14. Among 1,168 Pediatric Cardiology profiles paid that year, the median was $146 and the middle half received between $47 and $670.

Show as a table
Year Henaro Sabino Pediatric Cardiology median Middle half National median
2019 $194 $124 $35–$516 $163
2020 $307 $70 $23–$326 $114
2021 $321 $112 $27–$445 $132
2022 $306 $129 $36–$680 $149
2023 $589 $149 $38–$826 $160
2024 $862 $131 $37–$652 $164
2025 $14 $146 $47–$670 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $388 22 payments
  2. Supernus Pharmaceuticals, Inc. $378 10 payments
  3. Corium, Inc. $189 8 payments
  4. Ironshore Pharmaceuticals Inc. $157 8 payments
  5. Amgen Inc. $148 10 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $124 7 payments
  7. Merck Sharp & Dohme Corporation $123 8 payments
  8. E.R. Squibb & Sons, L.L.C. $119 1 payment
  9. Boston Scientific Corporation $104 6 payments
  10. Amarin Pharma Inc. $71 4 payments
  11. Other $790 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,592 119 payments
Products named General payments · program years 2019–2025
  1. LifeVest $388 22 payments
  2. Qelbree Viloxazine Hydrochloride $245 2 payments
  3. Azstarys $189 8 payments
  4. Repatha $148 10 payments
  5. QELBREE Psychology $133 8 payments
  6. VYVANSE $124 7 payments
  7. CAMZYOS $119 1 payment
  8. JORNAY PM $118 6 payments
  9. WATCHMAN Access System $90 5 payments
  10. VERQUVO $84 5 payments
  11. Other $1,397 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Cardiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record